Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
The co-existence of thalassaemia major and chronic myeloid leukaemia (CML) is a very rare event. We report a 32-year-old man with thalassaemia major whose progressively increasing leukocytosis and thrombocytosis led to the diagnosis of CML confirmed by the characteristic t(9;22)(q34;q11) chromosomal translocation and the bcr-abl (b3a2) DNA fusion. The patient was treated with hydroxyurea and anagrelide. This combination resulted in the satisfactory control of both the white blood cell and platelet counts, which has continued over the past 14 months with no major side-effects, albeit with no molecular response. The administration of hydroxyurea was also associated with a significant HbF increase.
Voskaridou
Ersi
E
Unit of Thalassaemia, Laikon General Hospital, Athens, Greece. dloukop@otenet.gr
Terpos
Evangelos
E
Komninaka
Veroniki
V
Eftyhiadis
Eftyhios
E
Mantzourani
Marina
M
Loukopoulos
Dimitris
D
D000328:Adult; D000986:Antisickling Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007958:Leukocyte Count; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D011799:Quinazolines / Q000627:therapeutic use*; D012074:Remission Induction; D013922:Thrombocytosis / Q000097:blood / Q000150:complications / Q000188:drug therapy; D017086:beta-Thalassemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy
D000986:Antisickling Agents; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea